Atlas Trials

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Clinical trial NCT03763643 · COMPLETED

Trial details

NCT number
NCT03763643
Sponsor
University of Minnesota
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Focal Segmental Glomerulosclerosis
Start date
2019-07-01
Primary completion
2025-02-07
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.